Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
作者信息
Richey Stephen L, Ng Chaan, Lim Zita D, Jonasch Eric, Tannir Nizar M
机构信息
The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
J Clin Oncol. 2011 Mar 10;29(8):e203-5. doi: 10.1200/JCO.2010.31.6091. Epub 2010 Dec 20.
Abstract
摘要
相似文献
1
Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
J Clin Oncol. 2011 Mar 10;29(8):e203-5. doi: 10.1200/JCO.2010.31.6091. Epub 2010 Dec 20.
2
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
BJU Int. 2011 Mar;107(5):747-748. doi: 10.1111/j.1464-410X.2011.10154.x.
3
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
Urologe A. 2004 Sep;43 Suppl 3:S145-6. doi: 10.1007/s00120-004-0608-4.
4
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
J Urol. 2008 Sep;180(3):867-72; discussion 872. doi: 10.1016/j.juro.2008.05.017. Epub 2008 Jul 17.
5
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Lancet Oncol. 2010 Apr;11(4):350-7. doi: 10.1016/S1470-2045(09)70383-3. Epub 2010 Feb 15.
6
A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
Am J Clin Oncol. 2009 Oct;32(5):453-9. doi: 10.1097/COC.0b013e3181925176.
7
A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Cancer. 2005 Feb 1;103(3):553-8. doi: 10.1002/cncr.20795.
8
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Am J Clin Oncol. 2011 Oct;34(5):443-8. doi: 10.1097/COC.0b013e3181e9c0d7.
9
Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
Lancet Oncol. 2010 Apr;11(4):307-8. doi: 10.1016/S1470-2045(10)70043-7.
10
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
Br J Cancer. 2004 Nov 15;91(10):1763-8. doi: 10.1038/sj.bjc.6602209.
引用本文的文献
1
Management of metastatic renal cell carcinoma - mini review.
J Kidney Cancer VHL. 2015 May 5;2(2):75-83. doi: 10.15586/jkcvhl.2015.28. eCollection 2015.
2
Chinese guidelines on the management of renal cell carcinoma (2015 edition).
Ann Transl Med. 2015 Nov;3(19):279. doi: 10.3978/j.issn.2305-5839.2015.11.21.
3
Adjuvant therapy for renal cell carcinoma: past, present, and future.
Oncologist. 2014 Aug;19(8):851-9. doi: 10.1634/theoncologist.2014-0105. Epub 2014 Jun 26.
4
Gemcitabine induced hemolytic uremic syndrome.
Am J Case Rep. 2012;13:89-91. doi: 10.12659/AJCR.882858. Epub 2012 May 25.
5
Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component.
J Cancer Res Clin Oncol. 2013 May;139(5):817-27. doi: 10.1007/s00432-013-1386-4. Epub 2013 Feb 9.
6
Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity.
EPMA J. 2011 Dec 22;3(1):1. doi: 10.1007/s13167-011-0137-3.
7
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.
Am J Clin Oncol. 2013 Oct;36(5):450-4. doi: 10.1097/COC.0b013e3182546a91.
8
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
Ann Oncol. 2012 Jun;23(6):1549-55. doi: 10.1093/annonc/mdr533. Epub 2011 Nov 5.
9
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.
BMC Cancer. 2011 Jul 14;11:295. doi: 10.1186/1471-2407-11-295.
本文引用的文献
1
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
J Clin Oncol. 2010 Feb 20;28(6):1061-8. doi: 10.1200/JCO.2009.23.9764. Epub 2010 Jan 25.
2
Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma.
Ann Oncol. 2010 Aug;21(8):1599-1606. doi: 10.1093/annonc/mdp600. Epub 2010 Jan 20.
3
Detection of chromosomal aberrations in renal tumors: a comparative study of conventional cytogenetics and virtual karyotyping with single-nucleotide polymorphism microarrays.
Arch Pathol Lab Med. 2009 Dec;133(12):1917-22. doi: 10.5858/133.12.1917.
4
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.
Cancer. 2010 Jan 1;116(1):57-65. doi: 10.1002/cncr.24685.
5
A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
Am J Clin Oncol. 2009 Oct;32(5):453-9. doi: 10.1097/COC.0b013e3181925176.
6
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
J Clin Oncol. 2008 Nov 20;26(33):5422-8. doi: 10.1200/JCO.2008.16.9847. Epub 2008 Oct 20.
7
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22.
8
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
J Urol. 2008 Sep;180(3):867-72; discussion 872. doi: 10.1016/j.juro.2008.05.017. Epub 2008 Jul 17.
9
Whole genome SNP arrays as a potential diagnostic tool for the detection of characteristic chromosomal aberrations in renal epithelial tumors.
Mod Pathol. 2008 May;21(5):599-608. doi: 10.1038/modpathol.2008.20. Epub 2008 Feb 8.
10
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Lancet. 2007 Dec 22;370(9605):2103-11. doi: 10.1016/S0140-6736(07)61904-7.
Zotero 插件